エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) August 2, 2023
UNITED STATES ANTIMONY CORPORATION |
(Exact name of registrant as specified in its charter) |
Montana |
|
001-08675 |
|
81-0305825 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification Number) |
P.O. Box 643 Thompson Fall, MT |
|
59873 |
(Address of principal executive officers) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (406) 827-3523
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.01 par value |
|
UAMY |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
United States Antimony Corporation (NYSE: UAMY) (“USAC” or the “Company”) announces the addition of Michael A. McManus, age 80, as an Independent Director to its board.
Item 8.01. Other Events
On August 2, 2023, the Company issued a press release announcing the addition of Michael A. McManus, age 80, as an Independent Director to the United States Antimony Corporation Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
UNITED STATES ANTIMONY CORPORATION |
|
|
|
|
|
|
August 2, 2023 |
By: |
/s/ Richard R. Isaak |
|
|
|
Richard R. Isaak |
|
|
|
Senior Vice President and Chief Financial Officer |
|
| 3 |
EXHIBIT 99.1
U.S. Antimony (UAMY) Announces Addition of
Michael A. McManus to Its Board of Directors
THOMPSON FALLS, MT / ACCESSWIRE / August 2, 2023 / United States Antimony Corporation ("USAC"), (NYSE: UAMY) is pleased to announce the addition of Michael A. McManus, age 80, as an Independent Director to its board.
Michael McManus is a recognized leader and builder of enterprises with successes as a public company CEO, senior government experience, a lawyer, new product development leader, and since 1998 a Board member for Novavax, a biotechnology company committed to help address serious infectious diseases globally through the discovery, development, and delivery of innovative vaccines to patients around the world. Mr. McManus has previously served as president, chief executive officer, and director at Misonix, Inc., a medical, scientific, and industrial provider of ultrasonic and air pollution systems, since 1998. Prior to that tenure, he was president and chief executive officer at New York Bancorp Inc. from 1991 to 1998. From 1990 through November 1991, Mr. McManus was president and chief executive officer at Jamcor Pharmaceuticals Inc. Previously, Mr. McManus served as an assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus received a BA in economics from the University of Notre Dame and a JD from the Georgetown University Law Center. He served in the US Army Infantry from 1968 through 1970. He is also a recipient of the Ellis Island Medal of Honor. Mr. McManus will stand for re-election at the next annual meeting of stockholders.
Chairman of the Board of USAC, Gary C. Evans, commented on Michael McManus’s addition to the board of directors, “With Michael McManus’s acceptance today as a new director on USAC’s board, the Company gains an outstanding talent and a seasoned veteran, with expertise and insight cultivated from the highest levels within top tier enterprises and institutions. His connections within our government should also prove to be valuable. USAC is now on a rigorous path to maximize the value of its existing assets, grow through acquisition, and with the additional guidance from Mr. McManus, we have secured additional proper oversight.”
About USAC:
United States Antimony Corporation, or USAC, was incorporated in Montana in January 1970 to mine and produce antimony products. In April 1998, the Company began to mine and smelt antimony in Mexico. Bear River Zeolite Company, or BRZ, was incorporated in 2000 as a wholly-owned subsidiary, and it is mining and producing zeolite in southeastern Idaho. In August 2005, USAC formed Antimonio de Mexico, S. A. de C. V. to explore and develop antimony and silver deposits in Mexico. Our principal business is the production and sale of antimony and zeolite products. In May 2012, the Company began trading on the NYSE under the symbol UAMY.
Forward-Looking Statements:
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events, including matters related to the Company's operations, pending contracts and future revenues, ability to execute on its increased production and installation schedules for planned capital expenditures and the size of forecasted deposits. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent filings, including Form 10-KSB with the Securities and Exchange Commission.
Contact:
United States Antimony Corp.
PO Box 643
47 Cox Gulch Rd.
Thompson Falls, Montana 59873- 0643
Melissa Pagen
(310) 628-2062
E-Mail: info@unitedstatesantimony.com
Source: United States Antimony Corporation